Nordic healthcare authorities want to negotiate shared deal over Bluebird Bio's gene therapy
Denmark, Sweden, Norway, Finland and Iceland will collectively negotiate with a pharmaceutical company over the price of a treatment for the first time.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
In an attempt to "reach acceptable and sustainable prices" and "secure fast and equal access to the treatment", health authorities in Denmark, Sweden, Norway and Finland have joined forces and invited US firm Bluebird Bio to the negotiating table.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
